Insulin icodec is a Recombinant Protein owned by Novo Nordisk, and is involved in 24 clinical trials, of which 22 were completed, and 2 are ongoing.

Insulin icodec (LAI-287) is an insulin receptor agonist. Insulins exert their specific action through binding to insulin receptors. Receptor-bound insulin lowers blood glucose by facilitating cellular uptake of glucose into skeletal muscle and adipose tissue. It inhibits the output of glucose from the liver. It also inhibits lipolysis in the adipocyte, inhibits proteolysis, and enhances protein synthesis.

The revenue for Insulin icodec is expected to reach a total of $8.8bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Insulin icodec NPV Report.

Insulin icodec is currently owned by Novo Nordisk.

Insulin icodec Overview

Insulin icodec (LAI-287) is under development for the treatment of type 1 and type 2 diabetes. It is administered subcutaneously. LAI-287 is a long-acting basal insulin analogue with potential for once weekly dosing. The drug candidate targets insulin receptor.

Novo Nordisk Overview

Novo Nordisk, a subsidiary of Novo Holdings AS, is a healthcare company focused on discovering, developing, and manufacturing of innovative biological medicines. It focuses on advancing drugs for the treatment of diabetes and other serious chronic conditions, including hemophilia, human growth hormone (HGH) disorders, and obesity. The company’s portfolio includes pre-filled delivery systems for insulin; glucagon hypokit; cartridge; needles; vials; insulin; estradiol for hormone replacement; recombinant drugs for hemophilia; glucagon; and oral antidiabetic agents. the company markets its products through subsidiaries in North America, Europe, Asia, Latin America, Africa, the Middle East and Australia. Novo Nordisk is headquartered in Bagsvaerd, Denmark.

The company reported revenues of (Danish Krone) DKK140,800 million for the fiscal year ended December 2021 (FY2021), an increase of 10.9% over FY2020. In FY2021, the company’s operating margin was 41.7%, compared to an operating margin of 42.6% in FY2020. In FY2021, the company recorded a net margin of 33.9%, compared to a net margin of 33.2% in FY2020. The company reported revenues of DKK45,566 million for the third quarter ended September 2022, an increase of 10.4% over the previous quarter.

Quick View – Insulin icodec

Report Segments
  • Innovator
Drug Name
  • Insulin icodec
Administration Pathway
  • Subcutaneous
Therapeutic Areas
  • Metabolic Disorders
Key Companies
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.